Todos os estudos
RecrutamentoFase III e fase IV (Integrado)Intervencionista

A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study

The RODEO clinical trial is testing a new way of taking medicines for chronic myeloid leukaemia (CML). Modern treatments, known as tyrosine kinase inhibitors (TKIs), are very effective at keeping CML stable. These include medicines like imatinib, dasatinib, nilotinib, bosutinib, and ponatinib. However, taking them at full strength every day can cause long-term, unpleasant side effects like tiredness, stomach aches, and muscle cramps. This study explores whether patients whose leukaemia is already stable can safely reduce their daily dose. Researchers will follow participants for 12 months after lowering the dose to check whether their leukaemia stays in check. The goal is to see if lower doses can maintain good health while reducing side effects. If successful, this trial could help doctors personalise treatment plans so people with CML take only as much medicine as they truly need.

Em resumo

Status
Recrutamento
Fase
Fase III e fase IV (Integrado)
Patrocinador
Stichting Radboud universitair medisch centrum
Meta de inscrição
136
Iniciar
26 Sep 2024

Sobre o que é este estudo?

Chronic myeloid leukaemia (CML) is a type of blood cancer that affects white blood cells. In the past, it was very difficult to treat, but modern targeted medicines called tyrosine kinase inhibitors (or TKIs) have transformed care. People with CML now often live long, full lives by taking a daily tablet such as imatinib, nilotinib, dasatinib, bosutinib, or ponatinib.

Even though these tablets work well to stop leukaemia cells from growing, they can cause daily side effects. Many people experience constant fatigue, sickness, joint aches, skin rashes, or fluid swelling. Because patients often need to take these medicines for years, doctors want to find ways to make daily life more comfortable without putting cancer control at risk.

The RODEO trial is investigating whether patients can safely take a lower dose of their current TKI medicine. Instead of a 'one-size-fits-all' dose, this study tests a tailored reduction guided by close medical monitoring. Researchers want to find out what proportion of patients can stay stable on a lower dose after 12 months without their leukaemia levels rising.

This research is important because it could change the standard way CML is managed across the NHS. If a reduced dose proves just as safe, many patients could experience fewer side effects, feel better day-to-day, and still keep their leukaemia firmly under control.

Pontos principais

  • The RODEO study tests whether lowering targeted leukaemia medicine doses is safe.
  • It is open to adults aged 18 and older with chronic myeloid leukaemia (CML).
  • Eligible medicines include imatinib, dasatinib, nilotinib, bosutinib, and ponatinib.
  • Participants will have regular, sensitive blood tests over at least 12 months to monitor their health.
  • If leukaemia levels start to rise, doctors will safely return the dose to its previous level.

Quem pode ser elegível?

This trial is open to adults aged 18 and older who have been diagnosed with chronic myeloid leukaemia (CML). Both men and women can take part. To be suitable, participants must already be taking one of the standard targeted leukaemia medicines: imatinib, nilotinib, dasatinib, bosutinib, or ponatinib.

Because the study involves lowering medicine doses, participants generally need to have stable leukaemia that is responding very well to their current treatment. If your leukaemia is not yet well controlled, or if you have only recently started treatment, lowering your dose might not be safe for you right now.

Your hospital specialist will check your medical history, your overall health, and your latest test results to make sure it is safe for you to take part. People with certain other complex medical conditions or those whose leukaemia has shown signs of resisting treatment may not be able to join.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I am aged 18 or older.
  2. I have been diagnosed with chronic myeloid leukaemia (CML).
  3. I am currently taking imatinib, nilotinib, dasatinib, bosutinib, or ponatinib.
  4. My leukaemia is currently stable and responding well to treatment.
  5. I am able to attend regular hospital appointments for blood tests and health checks.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part, you will work closely with your hospital haematology team to lower your daily medicine dose. You will not be asked to switch to an experimental drug; you will stay on your usual medicine, just at a reduced amount. Throughout the study, you will have regular hospital appointments so doctors can monitor your health closely.

At these visits, you will have standard blood tests, including sensitive molecular tests (often called BCR-ABL tests) that measure tiny amounts of leukaemia in your blood. You may also have physical checks and be asked to fill in simple questionnaires about your side effects and quality of life. The study monitors you for at least 12 months after your dose is first lowered. If your blood tests show that your leukaemia levels are beginning to rise, your doctor will immediately return you to your previous safe dose.

Riscos e benefícios potenciais

A potential benefit of joining this study is a reduction in medicine side effects, which may help you feel more energetic and improve your day-to-day wellbeing. You will also receive very close, regular monitoring from your specialist team. However, there is a risk that your leukaemia could become more active on a lower dose. If this happens, your medical team will spot it quickly on your blood tests and put your dose back up. Taking part is completely voluntary, and you can withdraw from the study at any time without it affecting the quality of your regular NHS care.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Países Baixos

Perguntas frequentes

What is the RODEO trial trying to find out?

The trial is checking whether people with stable chronic myeloid leukaemia can safely reduce their daily tablet dose without their cancer coming back.

What medicines are included in this study?

The study includes five standard targeted medicines: imatinib, dasatinib, nilotinib, bosutinib, and ponatinib.

What happens if my leukaemia levels go up after lowering the dose?

Your blood will be tested frequently. If tests show any signs that the leukaemia is increasing, your doctor will safely increase your dose back to its original level.

Will taking a lower dose cure my leukaemia?

No, this study is not designed to cure CML. Its purpose is to find the lowest effective dose to keep the leukaemia stable while causing fewer side effects.

Posso sair do estudo se mudar de ideia?

Yes. You can leave the trial at any point, for any reason, and your normal NHS care and treatment will continue as usual.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Patient guided dose reduction strategy of tyrosine kinase …" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.